389 related articles for article (PubMed ID: 15307143)
1. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
[TBL] [Abstract][Full Text] [Related]
2. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Brambilla E; Moro D; Gazzeri S; Brambilla C
J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
4. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
Makretsov NA; Huntsman DG; Nielsen TO; Yorida E; Peacock M; Cheang MC; Dunn SE; Hayes M; van de Rijn M; Bajdik C; Gilks CB
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6143-51. PubMed ID: 15448001
[TBL] [Abstract][Full Text] [Related]
5. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.
O-charoenrat P; Rusch V; Talbot SG; Sarkaria I; Viale A; Socci N; Ngai I; Rao P; Singh B
Clin Cancer Res; 2004 Sep; 10(17):5792-803. PubMed ID: 15355908
[TBL] [Abstract][Full Text] [Related]
6. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
7. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
[TBL] [Abstract][Full Text] [Related]
8. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.
Noh S; Shim H
Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426
[TBL] [Abstract][Full Text] [Related]
9. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
11. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
12. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
Dalquen P; Sauter G; Torhorst J; Schultheiss E; Jordan P; Lehmann S; Solèr M; Stulz P; Mihatsch MJ; Gudat F
J Pathol; 1996 Jan; 178(1):53-8. PubMed ID: 8778317
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of calbindin-D28k expression in lung cancer: analysis of 452 cases.
Castro CY; Stephenson M; Gondo MM; Medeiros LJ; Cagle PT
Mod Pathol; 2000 Jul; 13(7):808-13. PubMed ID: 10912942
[TBL] [Abstract][Full Text] [Related]
15. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
16. Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung.
Bellotti M; Elsner B; Paez De Lima A; Esteva H; Marchevsky AM
Mod Pathol; 1997 Dec; 10(12):1221-7. PubMed ID: 9436967
[TBL] [Abstract][Full Text] [Related]
17. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
Ionescu DN; Treaba D; Gilks CB; Leung S; Renouf D; Laskin J; Wood-Baker R; Gown AM
Am J Surg Pathol; 2007 Jan; 31(1):26-32. PubMed ID: 17197916
[TBL] [Abstract][Full Text] [Related]
18. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A gene expression in non-small cell lung carcinomas.
Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
[TBL] [Abstract][Full Text] [Related]
20. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
Kwon MS; Shin SH; Yim SH; Lee KY; Kang HM; Kim TM; Chung YJ
Lung Cancer; 2007 Jul; 57(1):46-53. PubMed ID: 17350713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
